Two naturally occurring molecules may help slow pancreatic cancer growth
Researchers at Texas A&M University report that two naturally occurring microRNAs, miR-15a and miR-16, may help restrain the growth of pancreatic ductal adenocarcinoma cells by reducing protein synthesis. The findings point to a potential treatment direction for a disease in which cancer cells are highly effective at growing and dividing.
The work, published in Physiological Reports, examined how the two small RNA molecules affect pancreatic cancer cells. The researchers found that increasing levels of miR-15a and miR-16 reduced protein production and slowed cell growth. They also reported that patients whose tumors had higher levels of the microRNAs tended to live longer, an association that supports further research into their biological role and therapeutic potential.
How microRNAs act as cellular regulators
MicroRNAs are short strands of genetic material that influence which proteins a cell makes. They do not carry protein-making instructions themselves. Instead, they can bind to genetic messages and keep those messages from being translated into proteins.
That makes microRNAs important regulators of cellular activity. Cancer cells need to sustain processes such as protein synthesis in order to proliferate. If those processes are disrupted, the rate at which cells can grow may be reduced.
In the Texas A&M study, miR-15a and miR-16 were found at reduced levels in pancreatic cancer. Raising their levels in pancreatic ductal adenocarcinoma cells reduced protein synthesis, according to the researchers. The result suggests that the molecules may function as part of a natural braking mechanism that is weakened in the disease.
What the study does and does not show
The findings are a research lead, not a new clinical treatment. The supplied study summary describes results in pancreatic cancer cells and an observed link between tumor microRNA levels and patient survival. It does not establish that increasing miR-15a or miR-16 will improve outcomes in patients.
Still, the work identifies a plausible mechanism worth investigating. Treatments that restore or mimic microRNA activity could, in principle, interfere with a cancer cell’s ability to maintain the protein production needed for rapid growth. Future research would need to determine how to deliver such molecules safely, whether they can act selectively on tumors, and how they perform in more complex disease models and clinical studies.
Why pancreatic ductal adenocarcinoma is the focus
Pancreatic ductal adenocarcinoma, or PDAC, is the form of pancreatic cancer studied by the team. The researchers focused on a central feature of cancer biology: continual proliferation. By tying miR-15a and miR-16 to the machinery of protein synthesis, the study narrows attention to a process cancer cells rely on directly.
The researchers’ survival observation gives the laboratory finding an additional clinical context. Higher levels of the two microRNAs in tumors were associated with longer survival in the patient data described in the report. Association alone cannot prove cause and effect, but it strengthens the case for investigating whether the molecules can be developed as biomarkers, treatment targets, or both.
A step toward new treatment strategies
Pancreatic cancer research often seeks vulnerabilities that can slow tumor growth without causing unacceptable harm to healthy tissue. Molecules already present in the body are particularly intriguing starting points because they are part of the systems that normally regulate gene expression.
The Texas A&M results suggest that miR-15a and miR-16 deserve more study as possible tools for putting pressure on pancreatic cancer cells’ growth program. The next steps will be to test how durable the effect is, understand which genetic messages are most important, and determine whether restoring these microRNAs can be translated into a safe therapeutic approach.
For now, the study offers a clearer view of two natural molecular regulators that appear to be diminished in pancreatic cancer and that, when increased in cancer cells, can reduce protein synthesis and slow growth.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
